Sinclair Research, provider of nonclinical services, has named Dr Scott E. Boley, DABT, as VP of toxicology. In this newly created role, he will have overall responsibility for driving the growth of Sinclair’s toxicology efforts and fostering relationships with new and current customers.
Dr Boley became a board-certified toxicologist in 2003 and has extensive expertise in drug development, as well as the regulatory expectations for a variety of test article types and indications. He will be applying his breadth of experience to benefit Sinclair customers.
“Scott is an experienced toxicologist who is well-known in the industry,” said Guy Bouchard, DVM, president of Sinclair Research Center.
“He is an expert in compound safety assessment with a deep regulatory understanding. Scott has advised sponsors with compound safety regulatory needs for the last 13 years and managed toxicology programs for 17 years. He will be an asset to our clients and their consultants.”
Scott joins Sinclair Research from MPI Research in Mattawan, Michagan. He joined MPI in 2005 as a study director in general toxicology and was promoted to senior director of general toxicology and infusion.
Serving as senior scientific adviser for the last 4 years and working with the business development arm of MPI, he helped sponsors to evaluate which non-clinical studies they needed for their test article.
Prior to MPI, Boley worked at Eli Lilly and Company where he was the toxicology lead on development teams for novel therapeutics designing, implementing and overseeing nonclinical safety studies.
